Form 4: Plus Therapeutics CFO Andrew Sims Reports Transaction in Company Stock

Andrew Sims, CFO of Plus Therapeutics, reported the acquisition of 4,098 shares of common stock at $1.27 per share on September 10, 2024.

Summary

• On September 10, 2024, Andrew Sims, the Chief Financial Officer of Plus Therapeutics, acquired 4,098 shares of the company's common stock.
• The purchase price was $1.27 per share.
• Following the transaction, Sims directly owns 9,815 shares of Plus Therapeutics.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a stock purchase by an officer. The purchase itself could be seen as slightly positive, but the document is primarily informational.

Positives

• The CFO's purchase of company stock could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Transaction, Plus Therapeutics, Andrew Sims, CFO